首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1425121

胚胎著床前基因檢測市場－2024年至2029年預測

Preimplantation Genetic Testing Market - Forecasts from 2024 to 2029

出版日期: 2024年01月25日 | 出版商:

Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計胚胎著床前基因檢測市場在預測期內將以 10.26% 的複合年成長率成長。

胚胎著床前遺傳學診斷 (PGD) 在 IVF 之前進行。對於多次流產且上次妊娠出現染色體異常的女性，PGD 被引入 IVF 週期。有遺傳性疾病風險的夫婦可以從胚胎著床前基因檢測中受益。

胚胎著床前基因檢測市場的促進因素

影響胚胎著床前基因治療產業成長的主要因素是不孕症發生頻率的增加和個體遺傳問題數量的增加。胚胎著床前基因檢測的需求量很大，因為它可以檢測有缺陷的胚胎以及多種遺傳性疾病和其他導致兒童出生時有健康缺陷的缺陷。單一基因捐贈者、患有性別相關遺傳疾病、染色體問題或多次流產的個體擴大利用胚胎著床前基因檢測方法。

新生兒死亡人數增加

許多遺傳畸形是導致全球新生兒死亡的原因，推動了胚胎著床前基因治療市場的成長。例如，根據聯合國兒童基金會的數據，2021 年每天將有 6,400 名新生兒死亡。此外，全球每 1,000 名活產嬰兒中有 18 人死亡，這使得出生後第一個月對新生兒來說是最危險的。胚胎著床前遺傳學診斷可以透過早期檢測染色體缺陷並預防胎兒先天性遺傳畸形來幫助遏制這一問題。隨著女性生育年齡的增加，胚胎著床前基因檢測的使用也增加。

增加聚合酵素鏈鎖反應的採用

在預測期內，聚合酵素鏈鎖反應將佔據最大的市場佔有率，因為成本效益的上升以及PCR測試的高市場滲透率和高精度正在推動其在胚胎著床前基因治療行業的佔有率。聚合酵素鏈鎖反應增加了檢測具有高拷貝數的特定基因拉伸的染色體異常的可能性。該技術適用於所有類型的基因診斷。

胚胎著床前遺傳學診斷的普及

推動胚胎著床前基因治療市場成長的主要因素是醫療保健專業人員和消費者對基因檢測的認知不斷提高。越來越多的單基因疾病和易位病例使得NGS技術在基因檢測方面變得有效。胚胎著床前遺傳學診斷（PGD）服務有助於降低遺傳疾病的發生率，這是透過胚胎測試來確定特定的基因突變來完成的。 PGS 服務也越來越受歡迎，因為提案接受多個 IVF 週期、高齡和反覆流產的夫婦使用。

醫療科技的進步

對改善衛生服務的需求不斷成長和收入的增加正在推動先進診斷和治療方法的發展。隨著預防身體異常和健康問題的需求增加，胚胎著床前基因治療市場見證了早期診斷方法的成長。這些早期診斷方法用於遺傳體外受精和其他形式的人工授精。胚胎著床前基因檢測方法可以檢測先天性聽力損失和囊腫纖維化等遺傳性疾病。

採用新一代定序技術

次世代定序儀以其高精度、高效和全面的遺傳訊息正在推動胚胎著床前基因治療產業的發展。次世代定序方法提供詳細的遺傳分析，可以提高輔助生殖技術的成功率。此外，由於胚胎著床前胚胎中染色體異常的需求不斷增加，螢光原位雜合技術的採用也對胚胎著床前基因治療市場產生了重大影響。 FISH 提供快速結果並一次篩檢有限數量的染色體。

IVF預後預測可望佔據較大市場佔有率

胚胎著床前基因檢測在IVF預後診斷中發揮重要作用，因為它需要檢測胚胎的醫學狀況，並有助於IVF預後診斷的成長。由於體外受精的高需求，對胚胎著床前基因檢測的需求不斷增加。此外，主要市場參與者推出的眾多產品進一步推動了胚胎著床前基因治療市場的成長。不孕症發生率的上升和對體外受精的日益偏好預計將在預測期內推動胚胎著床前基因治療市場的成長。

在歐洲，胚胎著床前基因檢測市場預計將穩定成長。

預計歐洲地區將在胚胎著床前基因治療市場佔據主要佔有率。該地區的胚胎著床前基因治療市場將因妊娠晚期盛行率的上升而受到推動。此外，歐洲國家日益寬鬆的篩檢法規以及強大市場參與者的存在正在推動該地區的胚胎著床前基因治療產業的發展。此外，由於生殖醫學的進步，預計亞太地區在預測期內將大幅成長。體外受精的高普及率和消費者意識的提高進一步推動了胚胎著床前基因治療市場的成長。

The major factor influencing the growth of the preimplantation genetic treatment industry is the growing frequency of infertility among individuals and rising genetic problems. Preimplantation genetic testing is growing in demand as it detects defective embryos and has some genetic disorders and other faults that lead to the child being born with health defects. Individuals who have single gene donors, sex-linked genetic disorders, chromosomal problems, or have a history of multiple abortions are increasingly using preimplantation genetic testing methods.

Growing prevalence of neo-natal deaths

Many genetic deformities cause newborn deaths around the globe and hence will propel the growth of the preimplantation genetic treatment market. For instance, according to UNICEF, 6,400 newborns died every day in 2021. Furthermore, there were 18 deaths per thousand live births worldwide making the first month the most dangerous for newborns. Preimplantation genetic diagnosis helps in curbing this issue as it detects defective chromosomes at an early stage and prevents congenital genetic deformities in the fetuses. As the women's age for childbearing increases so is the use of preimplantation genetic testing.

Rising adoption of polymerase chain reaction

Polymerase chain reaction is anticipated to hold the maximum market share during the forecast period owing to the high market penetration and rising cost-effectiveness with high accuracy of PCR tests are fueling the preimplantation genetic treatment industry share. The polymerase chain reaction increases the chance of detection of any chromosomal abnormalities with a large number of copies of a particular stretch of the genome. This technology is suitable for all types of genetic diagnosis.

Growing prevalence of preimplantation genetic diagnosis

The major factor driving the growth of the preimplantation genetic treatment market is the growing awareness among healthcare professionals and consumers about genetic testing. The rising incidence of single gene disease and translocation cases led to the effective delivery of NGS technology for genetic testing. The preimplantation genetic diagnosis (PGD) services help reduce the incidences of genetic diseases which is done by embryo examination to determine specific gene mutations. The PGS services are also gaining popularity as they are suggested for couples with multiple IVF cycles, advanced age, and recurrent pregnancy loss.

Advancements in medical technologies

The growing demand for improved medical services and increasing income is fueling opportunities for the development of advanced diagnostic and treatment approaches. As the need to prevent physical abnormalities and health problems has increased the preimplantation genetic treatment market has seen growth for early diagnostic approaches. These early diagnostic approaches are being used during genetic invitro fertilization and other artificial insemination procedures. Preimplantation genetic testing methods can detect inherited disorders including congenital hearing loss, cystic fibrosis, and many more.

Adoption of next-generation sequencing technology

Next-generation sequencing drives the preimplantation genetic treatment industry due to its high accuracy, efficiency, and comprehensive genetic information. The next-generation sequencing method provides detailed genetic analysis which results in improved success rates of assisted reproductive techniques. Moreover, the adoption of florescent in-situ hybridization is also significantly impacting the preimplantation genetic treatment market due to the growing need to detect chromosomal abnormalities in embryos before implantation. FISH offers rapid results and screens a limited number of chromosomes at a time.

IVF Prognosis is anticipated to hold a significant market share

Preimplantation genetic testing plays an important role in IVF prognosis as it is necessary to inspect the medical condition of the embryos, thereby contributing to the growth of IVF prognosis. The high demand for invitro fertilization procedures is increasing the demand for preimplantation genetic testing procedures in the market. Additionally, many product launches by major market players are further fueling the preimplantation genetic treatment market growth. Rising infertility and increasing preference for IVF procedures are expected to drive the growth of the preimplantation genetic treatment market during the forecast period.

In Europe, it is projected that the preimplantation genetic testing market will grow steadily.

The European region is anticipated to secure a sizable preimplantation genetic treatment market share. The regional preimplantation genetic treatment market will be fueled by the increasing prevalence of late pregnancies. Additionally, the growing liberal regulations in various countries in Europe for screening and the presence of leading market players are fueling the regional preimplantation genetic treatment industry. Furthermore, Asia Pacific is anticipated to grow significantly during the forecast period due to advancements in reproductive health. High adoption of IVF and increasing consumer awareness are further fueling the preimplantation genetic treatment market growth.

Market Key Developments

In April 2023, The HelpCureHD Foundation and Prelude Network launched the More Than Fertility campaign to increase and educate awareness about IVF with Preimplantation Genetic Testing.
In October 2022, Genomic Prediction and HelpCureHD collaborated to help partners with the risk of Huntington's disease screen through preimplantation genetic testing.
In October 2022, Ovation Fertility and Genomic Prediction partners to license the LifeView PGT platform.
In July 2022, To screen genetic diseases in IVF embryos, GenEmbryomics launched research using genome sequencing tests.

Segmentation:

By Technology

Next Generation Sequencing
Polymerase Chain Reaction
Fluorescent In-Situ Hybridization
Comparative Genomic Hybridization
Single Molecule Polymorphism

By Procedure Type

Preimplantation Genetic Screening
Preimplantation Genetic Diagnosis

By Application

Aneuploidy
Single Gene Disorders
X-linked Disorders
Others

By End-User

Maternity Clinics
Hospitals
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY

5.1. Introduction
5.2. Next Generation Sequencing
5.3. Polymerase Chain Reaction
5.4. Fluorescent In-Situ Hybridization
5.5. Comparative Genomic Hybridization
5.6. Single Molecule Polymorphism

6. PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE

6.1. Introduction
6.2. Preimplantation Genetic Screening
6.3. Preimplantation Genetic Diagnosis

7. PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION

7.1. Introduction
7.2. Aneuploidy
7.3. Single Gene Disorders
7.4. X-linked Disorders
7.5. Others

8. PREIMPLANTATION GENETIC TESTING MARKET, BY END-USER

8.1. Introduction
8.2. Maternity Clinics
8.3. Hospitals
8.4. Others

9. PREIMPLANTATION GENETIC TESTING MARKET, BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. United States
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. United Kingdom
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Spain
- 9.4.5. Others
9.5. The Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others